



UZH Life Sciences Fund and Schroder Adveq invest in ImmunOs Therapeutics AG to further support advancement of their immunotherapy platform for cancer

Schlieren (Zurich Area), Switzerland. – September 18, 2018 – ImmunOs Therapeutics AG, a Swiss biotechnology company leading development of a next generation innate and adaptive immunity focused immunotherapy platform for cancer, today announced that UZH Life Sciences Fund and Schroder Adveq will join the current group of investors. The proceeds of the financing will be used to advance its lead clinical candidate.

About ImmunOs Therapeutics AG:

ImmunOs Therapeutics AG is a biotechnology company focused on discovering and developing the next generation of novel human immunomodulatory proteins focused in innate and adaptive immunity. Our mission is to develop novel therapeutics that will improve the lives of patients with serious disease. We are a spin-off company of the University of Zurich.

ImmunOs Therapeutics AG lead program is a next generation, novel platform of multitasking biologics targeting diverse immunoregulatory receptors that activate anti-tumor responses built upon years of research and development. ImmunOs Proteins work directly on the Innate Immune System (MDSCs, Macrophages, NK Cells and Neutrophils) and Indirectly on the Adaptive Immune System by allowing the expansion of T cells, leading to strong anti-tumor responses as monotherapy and in combination with checkpoint inhibitors (PD-1, CTLA-4, PD-L1) and costimulatory agonists (e.g. 4-1BB) in multiple cancer indications. For more information, please visit www.immunotherapeutics.com.

About UZH Life Sciences Fund:

The University of Zurich and Novartis Venture Fund (NVF) share the common objective of fostering innovation in biotechnology and the life sciences in Switzerland. To better achieve this goal, UZH Foundation and NVF have established a fund that creates financing possibilities for UZH spin-off companies. The UZH Life Sciences Fund aims to promote innovation in the life sciences in the Zurich area.

About Schroder Adveq:

Schroder Adveq, founded in 1997 is a leading asset manager investing globally in private equity, having USD 8.6 billion of assets under management (as of December 31, 2017). Schroder Adveq's client base comprises institutional investors such as pension funds, insurance companies, endowments, family offices, and other financial institutions located in Europe, North America, and the

Asia-Pacific region. Schroder Adveq has offices in Zurich, Frankfurt, London, Jersey, New York, Beijing, and Hong Kong.

Further information can be found at: www.schroderadveq.com



Contact:

Investor Relations

Wagistrasse 14

8952 Schlieren (Zurich Area)

info@immunotherapeutics.com